Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess Steady-State Trough Concentrations, Safety, and Immunogenicity of Abatacept After Subcutaneous (SC) Administration to Subjects With Rheumatoid Arthritis (RA)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Meet ARA criteria for diagnosis of RA with active disease.~* RA diagnosis for at least 1 year.~* \> = 6 swollen joints.~* \> = 8 tender joints.~* Taking methotrexate (MTX) or MTX plus not more than 1 added oral DMARD for \> = 3 months and stable for 28 days prior to dosing.~Exclusion Criteria:~* Serious acute or bacterial infection in last 3 months.~* Chronic or recurrent bacterial infections.~* History of TB within previous 3 years or old TB not adequately treated.~* Specific lab test abnormalities~* History of cancer within 5 years.~* Exposure to CTLA4Ig (Cytotoxic T-lymphocyte (T-cell)-associated antigen 4Ig), belatacept, rituximab, efalizumab, alefacept, or other investigational drug or biologic.~* Treatment with hydroxychloroquine, azathioprine, leflunomide, immunoadsorption columns, mycophenolate mofetil, cyclosporine, D-Penicillamine or calcineurin inhibitors.~* Exposure to live vaccines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1 (weight < 60 kg) (Type: PLACEBO_COMPARATOR): None
- Group 2 (weight < 60 kg) (Type: PLACEBO_COMPARATOR): None
- Group 3 (weight 60-100 kg) (Type: PLACEBO_COMPARATOR): None
- Group 4 (weight > 100 kg) (Type: PLACEBO_COMPARATOR): None
- Group 5 (weight > 100 kg) (Type: PLACEBO_COMPARATOR): None
- Abatacept (Type: EXPERIMENTAL): Long Term

Based on this trial design, predict the completion outcome and termination type (if applicable).